Treatment of ankylosing spondylitis


SARI İ., ÖZTÜRK M. A., Akkoc N.

TURKISH JOURNAL OF MEDICAL SCIENCES, vol.45, no.2, pp.416-430, 2015 (SCI-Expanded) identifier identifier identifier

  • Publication Type: Article / Review
  • Volume: 45 Issue: 2
  • Publication Date: 2015
  • Doi Number: 10.3906/sag-1401-79
  • Journal Name: TURKISH JOURNAL OF MEDICAL SCIENCES
  • Journal Indexes: Science Citation Index Expanded (SCI-EXPANDED), Scopus, TR DİZİN (ULAKBİM)
  • Page Numbers: pp.416-430
  • Keywords: Ankylosing spondylitis, treatment, nonsteroid antiinflammatory drugs, disease modifying antirheumatic drugs, corticosteroids, anti-TNF agents, NONSTEROIDAL ANTIINFLAMMATORY DRUGS, PLACEBO-CONTROLLED TRIAL, NECROSIS-FACTOR-ALPHA, METHYLPREDNISOLONE PULSE THERAPY, RANDOMIZED CONTROLLED-TRIAL, GUIDED CORTICOSTEROID INJECTION, UPPER GASTROINTESTINAL TOXICITY, REDUCES SPINAL INFLAMMATION, LOW-DOSE INFLIXIMAB, ETANERCEPT 50 MG
  • Dokuz Eylül University Affiliated: Yes

Abstract

Ankylosing spondylitis is a chronic, inflammatory, rheumatic disease that can reduce the quality of life and increase the risk of disability and mortality. It also causes direct and indirect economic losses due to health expenses and as a result of workforce loss. Management of this disease consists of pharmacological and nonpharmacological modalities. Until recently, pharmacological treatment options have been very limited. However, development of novel biological drugs revolutionized the management of this disease. The aim of this review article is to present an updated overview of the pharmacologic treatment of ankylosing spondylitis. Nonpharmacological treatment modalities including physiotherapy and exercise are only briefly mentioned and surgical treatment is not discussed.